Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

The Trojan Horse of Kidney Transplantation Returns: A Review and Call for Financial Neutrality

Danovitch GM. The Trojan Horse of Kidney Transplantation Returns: A Review and Call for Financial Neutrality. Clin J Am Soc Nephrol. 2024 Nov 22. doi:[...]

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

Pollack CV Jr, Arroyo D, Kanda E, Lázaro IJS, Lesén E, Franzén S, Gray CM, Lipińska A, Murohara T, Rastogi A. Duration of sodium zirconium[...]

Advancing Equitable Kidney Care through Population Health Approaches in Los Angeles County’s Safety Net System

Kalantar-Zadeh K, Raff EA, Chong CC, Yang JK, Le TK, Barba LM, Pham PC, Dhamija R, Ghaffari A, Khine A, Patel N, Nicholas SB, Sim[...]